<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="771">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646711</url>
  </required_header>
  <id_info>
    <org_study_id>M02-461</org_study_id>
    <nct_id>NCT00646711</nct_id>
  </id_info>
  <brief_title>Pediatric Switch Study for Children and Adolescent Patients With Epilepsy</brief_title>
  <official_title>A 14 Day Randomized, Open-Label, Cross-Over, Single Center, Outpatient Study of Depakote Delayed-Release or Depakote Sprinkle vs. Divalproex Sodium Extended-Release in Child and Adolescent Patients With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the tolerability of switching from Depakote Sprinkle Capsules or Depakote tablets
      to Depakote ER tablets in the pediatric population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of seizures</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Pediatric Epilepsy</condition>
  <arm_group>
    <arm_group_label>Sequence Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depakote Delayed Release/Depakote Sprinkle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depakote ER</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depakote Delayed-Release/Depakote Sprinkle</intervention_name>
    <description>Administered according to the subject's usual regimen.</description>
    <arm_group_label>Sequence Group I</arm_group_label>
    <other_name>ABT-711</other_name>
    <other_name>Depakote DR</other_name>
    <other_name>Depakote Sprinkle</other_name>
    <other_name>divalproex sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depakote ER</intervention_name>
    <description>Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.</description>
    <arm_group_label>Sequence Group II</arm_group_label>
    <other_name>ABT-711</other_name>
    <other_name>Depakote Extended Release</other_name>
    <other_name>divalproex sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient with a clinical diagnosis of epilepsy considered stable by the
             investigator.

          -  Must be in good physical health, on the same dose of all medications, including
             Depakote and other AEDs, for 2 week period prior to randomization.

          -  Minimum body weight of 37 lbs.

        Exclusion Criteria:

          -  Six-month history of drug or alcohol abuse.

          -  Status epilepticus within 6 months prior to screening.

          -  Abnormal platelet or ALT/AST levels.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <lastchanged_date>March 25, 2008</lastchanged_date>
  <firstreceived_date>March 25, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Sharon Stec, Assoc Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
